Quick Answer
Ultragenyx Pharmaceutical Inc. reported Operating Income of -$535.00 million for fiscal year 2025.
Ultragenyx Pharmaceutical Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$535.00M | +0.2% |
| 2024 | -$536.00M | +5.8% |
| 2023 | -$569.00M | +12.3% |
| 2022 | -$648.92M | -70.0% |
| 2021 | -$381.74M | -15.6% |
| 2020 | -$330.12M | +22.2% |
| 2019 | -$424.17M | -14.2% |
| 2018 | -$371.37M | -12.9% |
| 2017 | -$328.94M | -32.6% |
| 2016 | -$248.01M | -67.9% |
| 2015 | -$147.74M | -160.2% |
| 2014 | -$56.78M | -75.9% |
| 2013 | -$32.28M | -101.9% |
| 2012 | -$15.98M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$170.89M | -29.5% | -58.4% |
| June 30, 2025 | -$107.89M | +7.3% | +24.5% |
| March 31, 2025 | -$142.94M | +13.6% | -8.3% |
| September 30, 2024 | -$131.99M | +9.0% | -13.4% |
| June 30, 2024 | -$116.36M | +21.4% | +29.6% |
| March 31, 2024 | -$165.35M | -7.3% | -14.0% |
| September 30, 2023 | -$145.10M | +35.5% | +1.9% |
| June 30, 2023 | -$147.96M | -4.5% | +4.0% |
- Ultragenyx Pharmaceutical Inc. showed an increase of +0.2% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Ultragenyx Pharmaceutical Inc.’s operating income has declined by 3246.9% (from -$15.98 million to -$535.00 million).
- The most recent figure is from Ultragenyx Pharmaceutical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: